Optimizing Coronary Artery Disease Treatment 2026

Roughly 5% of U.S. adults aged 20 and older live with coronary artery disease, and U.S. heart disease treatment and care costs exceeded $168 billion between 2021 and 2022, according to CardioCare's summary of coronary artery disease treatment. For hospital boards, that figure changes the frame. Coronary artery disease treatment isn't just a cardiology topic. It's a service line, throughput, quality, and workforce issue that directly affects margin, reputation, and referral retention.

The strategic question isn't whether a system offers CAD care. Most already do. The differentiator is whether the organization can deliver the full pathway reliably: evidence-based medical therapy, timely revascularization, multidisciplinary selection, and durable secondary prevention. Systems that treat CAD as a fragmented sequence of encounters usually underperform. Systems that treat it as an integrated operating model usually build stronger clinical outcomes and a more defensible cardiovascular franchise.

Table of Contents

• The Strategic Imperative of CAD Treatment

• Guideline Directed Medical Therapy as the Foundation - What the baseline standard now requires - Why boards should treat GDMT as an operating metric

• Operationalizing Secondary Prevention and Lifestyle Protocols - Lifestyle support is a delivery model, not a brochure - Where secondary prevention often breaks down

• Comparing Revascularization Strategies PCI vs CABG - PCI as a speed and access platform - CABG as a completeness strategy for complex disease - What this means for service line design

• Optimizing Outcomes Through Patient Stratification - The Heart Team as an operational asset - Stratification is where quality becomes visible

• Integrating Advanced and Emerging CAD Therapies - The treatment model is widening - How forward-looking programs respond

• Building a High-Performance CAD Treatment Program - Closing the treatment gap requires process ownership - The talent model has to match the clinical promise - A board-level blueprint

The Strategic Imperative of CAD Treatment

Coronary artery disease treatment belongs on the same agenda as capital planning and physician recruitment. The disease burden is too large, the cost exposure is too high, and the treatment pathway is too operationally complex to leave inside a narrow clinical silo.

CardioCare's CAD treatment overview notes two facts that matter to boards: roughly 5% of U.S. adults aged 20 and older live with coronary artery disease, and heart disease treatment and care costs exceeded $168 billion between 2021 and 2022. The same summary reports that revascularization success rates exceed 95% in appropriate cases, which makes execution quality highly consequential for systems that can identify the right patients and move them efficiently into treatment through this coronary artery disease treatment overview.

That combination, broad prevalence, high spend, and technically effective intervention, creates a strategic reality. CAD is one of the clearest examples in modern hospital medicine where clinical excellence and operational discipline must be built together.

Board implication: A cardiology service line can't claim strength in coronary artery disease treatment if it measures cath lab volume but not medication uptake, referral capture, post-discharge follow-through, and multidisciplinary case selection.

The most competitive programs don't define CAD narrowly as an interventional business. They define it as a longitudinal care platform. That shifts investment priorities. It promotes ambulatory cardiology, advanced practice support, care coordination, pharmacist involvement, and cardiothoracic alignment from support functions to core infrastructure.

Guideline Directed Medical Therapy as the Foundation

A modern CAD program starts with guideline-directed medical therapy, not with the cath lab schedule. Revascularization matters, but it's not the base layer of care. Medical therapy remains the default platform on which every subsequent decision rests.

What the baseline standard now requires

StatPearls' review of coronary artery disease management describes a treatment framework built around low-dose aspirin, beta-blockers, nitroglycerin as needed, and moderate-to-high-intensity statins, with current guidance recommending aspirin 81 to 162 mg daily indefinitely for patients who can tolerate it, beta-blockers for at least 3 years after myocardial infarction, and statins for nearly all patients with established atherosclerotic cardiovascular disease when tolerated through the StatPearls CAD treatment review.

A significant shift came with the 2013 ACC/AHA cholesterol guideline, which moved CAD management away from LDL target chasing and toward an intensity-based approach. In practical service line terms, that change simplified a common source of variation. The question became less about whether a patient had reached a particular number and more about whether the patient with established ASCVD was receiving the appropriate statin intensity.

The evidence for that standard isn't abstract. StatPearls cites the MIRACL trial, where 80 mg of atorvastatin produced a 2.6% absolute risk reduction in early post-acute coronary syndrome events versus placebo. For operators focused on bed capacity and avoidable downstream utilization, that's the point. Strong medical therapy changes event trajectories before another procedure is even under discussion.

Why boards should treat GDMT as an operating metric

Many hospitals still talk about GDMT as if it were solely physician preference. It isn't. It's process reliability.

A high-functioning program usually hardwires several behaviors:

• Admission standardization: CAD order sets make aspirin, statin therapy, beta-blocker assessment, and symptom-directed antianginal therapy hard to miss.

• Discharge discipline: Medication reconciliation confirms that evidence-based agents are prescribed, documented, and explained before the patient leaves.

• Ambulatory continuity: Follow-up clinics verify tolerance, titration, adherence, and persistence rather than assuming the initial prescription solved the problem.

Strong coronary artery disease treatment programs don't wait for a restenosis or reinfarction to reveal that medical therapy failed. They identify failure at discharge, in refill behavior, and in early follow-up.

The staffing implication is straightforward. A system can't reliably deliver GDMT with interventional talent alone. It needs general cardiologists, hospitalists who understand CAD pathways, clinical pharmacists, advanced practice providers, and outpatient teams that can handle medication optimization after hospitalization.

Operationalizing Secondary Prevention and Lifestyle Protocols

Medication alone doesn't complete the job. Secondary prevention succeeds when hospitals convert broad advice into repeatable programs with assigned owners, referral criteria, and closed-loop follow-up.

Lifestyle support is a delivery model, not a brochure

Many organizations still treat exercise counseling, smoking cessation, nutrition support, and risk-factor coaching as educational side notes. That approach leaves too much dependent on patient initiative after discharge. A stronger model places these functions inside the service line itself, with referral workflows that begin during hospitalization or immediately after outpatient diagnosis.

For coronary artery disease treatment, lifestyle protocol design matters because the patient journey is long. If a health system wants fewer avoidable returns, fewer breakdowns in adherence, and more durable stabilization, it needs structured handoffs into cardiac rehabilitation, dietitian support, tobacco treatment resources, and nurse-led check-ins.

A useful example is the relational side of follow-up. Hospitals that strengthen communication continuity often improve trust and adherence. That's one reason leadership teams should look beyond purely technical metrics and examine care team interaction patterns, including the role of nurse-patient relationships in sustained cardiac care.

Where secondary prevention often breaks down

The usual failure points are operational, not conceptual.

• Referral leakage: Cardiac rehabilitation and counseling services exist, but no one owns completion.

• Fragmented documentation: Risk-factor plans live in narrative notes instead of a structured pathway visible across inpatient and outpatient settings.

• Insufficient staffing: APPs, nurses, and pharmacists don't have protected time to manage prevention work that falls outside procedural encounters.

A mature service line treats secondary prevention as capacity management. Every patient stabilized through noninvasive and outpatient pathways preserves room for higher-acuity work. Every patient who understands the regimen and receives coordinated support is less likely to re-enter the system in crisis.

The systems that perform best in CAD often make the least glamorous work the most reliable: counseling, scheduling, medication review, rehab referral, and follow-up contact.

Comparing Revascularization Strategies PCI vs CABG

The PCI versus CABG decision is often framed as a technical comparison. For executives, it's also a platform decision about what kind of cardiovascular service line the organization intends to run.

PCI as a speed and access platform

Percutaneous coronary intervention offers a rapid route to revascularization through balloon angioplasty and stent placement. Johns Hopkins, as summarized in the verified data, notes that a stent is placed at the narrowing site nearly 90% of the time in stent-based treatment, which reflects how routine PCI has become in modern practice. Operationally, PCI depends on a well-run catheterization lab, interventional cardiology coverage, nursing competency in procedural recovery, and dependable transfer logistics from emergency departments and feeder sites.

The organizational advantage of PCI is responsiveness. It lets systems address discrete lesions quickly, manage symptomatic disease efficiently, and build strong regional referral relationships. In markets where emergency cardiovascular transfer patterns are still fluid, PCI capability often becomes a service line anchor because referring clinicians know the destination can act immediately.

CABG as a completeness strategy for complex disease

CABG serves a different clinical and operational purpose. According to Mayo Clinic's CAD diagnosis and treatment guidance, PCI and CABG are the key revascularization options for severe disease, and CABG is generally favored for extensive multivessel disease because it creates an alternative blood-flow route when medical therapy is insufficient to maintain myocardial perfusion.

That distinction matters. CABG isn't just another way to restore flow. It's often the preferred strategy when anatomy is broader, disease is more complex, or the desired endpoint is more extensive revascularization than a focal catheter-based fix can provide.

For a hospital board, CABG capability signals a higher level of cardiovascular maturity. It requires cardiothoracic surgery, perfusion, ICU support, OR access, anesthesia alignment, step-down capacity, and post-acute coordination. The threshold for sustaining that model is much higher than maintaining a PCI-focused program.

What this means for service line design

The two approaches should be compared less like competitors and more like coordinated assets.

Dimension	PCI	CABG
Primary infrastructure	Cath lab and interventional cardiology	OR, cardiothoracic surgery, perfusion, ICU
Typical organizational strength	Speed, access, transfer responsiveness	Comprehensive treatment for complex anatomy
Best strategic use	High-throughput coronary intervention pathway	Advanced tertiary or quaternary cardiac capability
Failure risk if underbuilt	Delays, inconsistent coverage, fragmented follow-up	Case selection problems, ICU strain, surgical bottlenecks

Several planning implications follow:

• Don't build PCI in isolation: If post-PCI follow-up is weak, the system captures the procedure but loses the longitudinal value.

• Don't build CABG without referral depth: Surgical capability without steady complex-case volume creates staffing and utilization stress.

• Align incentives across specialties: Interventional cardiology and cardiothoracic surgery should be measured on program performance, not siloed procedural wins.

• Use transfers strategically: Community hospitals may not need full CABG capability, but they do need formal pathways into centers that can provide it.

A state-of-the-art CAD program doesn't ask whether PCI or CABG matters more. It asks whether the system can identify which patient needs which pathway, then deliver that pathway without delay or drift.

Optimizing Outcomes Through Patient Stratification

The most expensive error in coronary artery disease treatment isn't necessarily a failed procedure. It's choosing the wrong pathway for the wrong patient because the decision process was fragmented.

The Heart Team as an operational asset

For complex CAD, the Heart Team model should be treated as an operating standard, not as a branding exercise. Interventional cardiologists, cardiothoracic surgeons, general cardiologists, cardiac imaging specialists, anesthesiologists, and advanced practice leaders each see a different part of risk. When those views remain separated, treatment decisions tend to follow local convenience. When they're brought together, decisions are more likely to reflect anatomy, comorbidity burden, procedural suitability, recovery expectations, and long-term management feasibility.

The practical value is substantial. Heart Team review reduces the odds that a patient arrives in surgery without full catheterization context, or receives PCI when surgical consultation would have changed the recommendation. It also improves patient communication. A unified recommendation is easier to explain and easier for referring physicians to trust.

Stratification is where quality becomes visible

High-performing programs formalize patient stratification rather than leaving it to ad hoc conversation. In many centers, that means using structured risk review, including tools such as the SYNTAX score for anatomic complexity, while combining those assessments with clinical judgment about frailty, ventricular function, diabetes status, renal disease, and recovery support.

The larger point is organizational. Stratification should drive resource deployment.

• Low-complexity disease: Often moves through efficient medical management and selective PCI pathways.

• Intermediate complexity: Benefits from deliberate case conference review, especially when anatomy and comorbidity pull in different directions.

• High-complexity multivessel disease: Usually requires early cardiothoracic input, inpatient coordination, and clearer post-acute planning.

Service line leaders can distinguish a destination program from a procedural shop. A destination program has case conference cadence, shared imaging review, documented recommendations, and escalation rules when opinions diverge. It also has the culture to support joint decision-making without procedural tribalism.

The Heart Team works best when it has authority. If conference recommendations are optional and undocumented, the meeting becomes educational rather than operational.

Integrating Advanced and Emerging CAD Therapies

The static version of coronary artery disease treatment, statin, stent, bypass, no longer captures where the field is headed. Cardiometabolic therapy is changing the shape of secondary prevention, and hospital strategy should change with it.

The treatment model is widening

In late 2025, the American Heart Association highlighted a New England Journal of Medicine study showing that oral semaglutide reduced the risk of nonfatal heart attack, stroke, or cardiovascular death in people with type 2 diabetes at high cardiovascular risk, as reported in the AHA research roundup on new ways to treat old problems. The same roundup emphasized continued work on GLP-1 receptor agonists and other cardiometabolic therapies.

That matters for service line planning because many CAD programs still organize themselves around anatomy first and metabolism second. The emerging model is broader. It treats cardiometabolic risk reduction as part of core cardiovascular management, especially for patients whose disease burden extends beyond coronary stenosis alone.

How forward-looking programs respond

Boards don't need to turn every cardiology department into a research institute. They do need to ensure the program can absorb meaningful therapeutic change without operational lag.

That usually requires three moves:

1. Expand clinic capability around cardiometabolic disease. General cardiology, preventive cardiology, endocrinology collaboration, and pharmacy support need tighter alignment.

2. Update physician and APP education. If newer therapies affect secondary prevention pathways, prescribing confidence and workflow support have to keep pace.

3. Refine patient identification. Programs need registries or panel-management workflows that flag high-risk patients who may benefit from newer options.

For leaders tracking the operational implications of this drug class, ACG has also published a perspective on GLP-1 receptor agonists and heart failure cost trends. The strategic takeaway is simple: pharmacologic innovation is no longer peripheral to cardiovascular service design.

A forward-looking CAD program also pays attention to advanced imaging and diagnostics, especially where patient selection is uncertain or symptoms don't align neatly with classic obstructive patterns. The exact tools will differ by market and academic ambition, but the organizational principle is stable. Programs that can evaluate more precisely can intervene more selectively.

Building a High-Performance CAD Treatment Program

Coronary artery disease remains one of the largest drivers of cardiovascular volume, cost, and downstream utilization. For hospital boards, that makes CAD treatment less a single clinical service and more a test of whether the organization can convert evidence into repeatable performance at scale.

Closing the treatment gap requires process ownership

A UCLA summary of studies on underutilization of therapies in CAD patients points to a persistent gap between recommended therapy and actual care. The same summary notes that having a documented LDL value was associated with a higher likelihood of treatment, and care at a teaching hospital was associated with better use of therapy.

Those findings matter operationally. If LDL documentation changes treatment rates, the constraint is not only physician knowledge. It is lab capture, EHR visibility, discharge workflow, and who is accountable for acting on the result. If teaching hospitals perform better, boards should ask which capabilities explain the difference: protocol design, pharmacist support, APP coverage, specialist access, or stronger follow-up systems.

That leads to a more useful management question than "Are our clinicians aware of the guidelines?" The better question is whether the care model makes guideline-concordant treatment the default.

Hospitals building a serious CAD program should test four areas:

• Point-of-care data reliability: Are lipid values, prior revascularization history, contraindications, and medication status visible when decisions are made?

• Discharge execution: Does every CAD discharge trigger medication reconciliation, follow-up scheduling, rehab referral, and clear ownership of dose adjustment?

• Post-acute management: Is there a defined team responsible for titration, adherence checks, and persistence monitoring across the first months after discharge?

• Practice variation control: Do community sites, non-teaching units, and employed clinics follow the same protocols as the flagship campus?

A useful rule for leadership is simple. If no one can name the owner of GDMT initiation, titration, and follow-up, performance will vary by physician and by site.

The talent model has to match the clinical promise

High-performing CAD programs are built around coverage models, not isolated hires. A hospital can recruit an excellent interventionalist and still underperform if outpatient CAD management, inpatient transitions, pharmacy oversight, and surgical coordination remain thin.

The staffing architecture usually needs general cardiologists to manage longitudinal CAD, interventional cardiologists for PCI, cardiothoracic surgeons where CABG is part of the service line, APPs who bridge inpatient and ambulatory settings, clinical pharmacists who support medication optimization, cardiac rehabilitation staff, and nurses trained in both acute coronary syndrome workflows and chronic secondary prevention. In practical terms, the service line succeeds when each handoff has an owner and each owner has protected capacity.

Recruitment should follow the intended program design. Systems planning to expand complex coronary care often need to hire in coordinated groups rather than one role at a time. For leaders assessing how to align hiring with care model design, strategies for building a resilient cardiology team can help systems source talent that fits the clinical, operational, and geographic realities of the program.

A board-level blueprint

Strong CAD programs tend to share five operating characteristics:

• Protocolized medical management: GDMT is built into order sets, discharge checklists, outpatient follow-up, and escalation pathways.

• Disciplined revascularization governance: PCI and CABG decisions are guided by defined criteria, multidisciplinary review, and consistent documentation.

• Secondary prevention capacity: Rehabilitation, smoking cessation, nutrition support, and adherence monitoring are treated as throughput and outcomes functions, not optional extras.

• Management visibility: Leaders can see variation in therapy uptake, referral completion, readmissions, and handoff reliability by site and provider group.

• Staffing tied to strategy: Hiring plans reflect the actual service mix the organization intends to deliver, including longitudinal disease management and procedural growth.

Many organizations still evaluate CAD strength through cath lab volume and procedural reputation. Patients and payers experience program quality across the full pathway. The hospitals that gain share over time are usually the ones that connect clinical rigor to operating discipline, physician alignment, workforce design, and measurable follow-through after discharge.

Hospitals building or expanding a cardiovascular service line need talent strategies that match the complexity of modern coronary artery disease treatment. American Cardiology Group works exclusively in cardiology and cardiac surgery recruitment, supporting health systems that need interventional cardiologists, cardiothoracic surgeons, general cardiologists, and advanced practice providers to strengthen continuity, access, and long-term program growth.